A watershed in fighting cancer – but a miracle cure is a long way off | Charles Swanton

The latest advance in immunotherapy offers great hope, but there is much to learn before it can be translated into treatmentThese are exciting times to be a cancer researcher. The news this week that awoman ’s advanced breast cancer has apparently been eradicated by a therapy derived from her own immune system is a development many of us have waited a long time to hear. It ’spersonalised medicine, taken to the absolute limit, and a huge testimony to decades of hard work by a team of US researchers. And it ’s the sort of advance that genuinely deserves to be called a breakthrough.But those of us who treat people with advanced cancer have to balance the optimism of scientific progress with sober reality – this isn’t yet a cancer “treatment”, in the sense that is meaningful to our patients. The techniques used byDr Steve Rosenberg’s team at the US National Cancer Institute, and which many of us in the UK (including my own team) are also working on, are fearsomely complex, and currently far outside the routine clinical reality of an NHS cancer centre. That’s not because of funding, staff levels, or any of the other critic isms often levelled at our overstretched healthcare system – it’s because of the speed with which these insights have arrived. Naturally there will be a period of catch-up while they are tested more widely, and the infrastructure todeliver them routinely is put in place.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cancer research Breast cancer Medical research NHS Science Health Society UK news World news Source Type: news

Related Links:

AbstractIncreasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a novel HER2-targeting ADC bearing a potent anthracycline derivate as payload (T-PNU) in a human HER2-expressing syngeneic breast cancer model resistant to trastuzumab and ado-trastuzumab emtansine. Mechanistically, the anthracycline component of the novel ADC induced immunogenic cell death leading to exposure and secretion of danger-associated molecular signals. RNA sequencing derived immunogenomic signatures an...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSIONS TCL-based immunotherapy has discrepant anti-tumor efficiency in different TNBC cell lines by PDL-1/PD interaction, providing the theoretical basis of TCL-based immunotherapy in TNBC. PMID: 30653481 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
Truly personalized therapy — an end to the era of one size fits allTruly personalized therapy — an end to the era of one size fits all, Published online: 15 January 2019; doi:10.1038/s41571-018-0165-1In 2018, several trials in breast cancer have shown efficacy of strategies that rely on novel markers, including gene expression assays or pathological complete response. The relevance of targeted strategies in patient subgroups and of immunotherapy efficacy were demonstrated.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research
AbstractCancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents. In this article, we first summarize the current understanding of virus biology and viral genes involved in host-virus interactions to further improve the utility of these agents in therapeutic applications. We then discuss recent findings from basic and clinical studies using VV as cancer vaccines and oncolytic immunotherapies. Despite encouraging results ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsIn summary, EnanDIM ® comprise a novel family of TLR9 agonists that facilitate an efficacious activation of both innate and adaptive immunity. Their proven potential in onco-immunotherapy, as shown by cytotoxic activity, beneficial modulation of the tumor microenvironment, inhibition of tumor growth, and induction of long-lasting, tumor-specific memory, supports EnanDIM® molecules for further preclinical and clinical development.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Our data indicated that the level of B7 family members can predict the prognosis of breast cancer patients, and miR-195/miR-497 regulate CD274 expression in triple negative breast cancer. This regulation may further influence tumor progression and the immune tolerance mechanism in breast cancer and may be able to predict the effect of immunotherapy on patients. PMID: 30607158 [PubMed]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
Authors: Allahverdiyev A, Tari G, Bagirova M, Abamor ES Abstract Cancer is the leading cause of death worldwide. In developed as well as developing countries, breast cancer is the most common cancer found among women. Currently, treatment of breast cancer consists mainly of surgery, chemotherapy, hormone therapy, and radiotherapy. In recent years, because of increased understanding of the therapeutic potential of immunotherapy in cancer prevention, cancer vaccines have gained importance. Here, we review various immunotherapeutic breast cancer vaccines including peptide-based vaccines, whole tumor cell vaccines, gen...
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research
By BISHAL GYAWALI MD  Long list of news in lung cancer September was an important month in oncology—especially for lung cancer. The World Conference in Lung Cancer (WCLC) 2018 gave us some important practice-changing results, also leading to four NEJM publications. The trial with most public health impact is unfortunately not published yet. It’s the NELSON trial that randomised more than 15000 asymptomatic people at high risk of lung cancer to either CT-based screening for lung cancer or to no screening and found a significant reduction in lung cancer mortality rates among the screened cohort com...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Research Bishal Gyawali Breast cancer Cancer drugs Clinical Trials health spending immunotherapy Lung cancer Oncology pembrolizumab Source Type: blogs
More News: Breast Cancer | Cancer | Cancer & Oncology | Funding | Immunotherapy | Learning | Research | Science | Universities & Medical Training